Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave s Revenues, Net Loss Up in Q4

NEW YORK, Feb. 24 (GenomeWeb News) - Third Wave Technologies today reported increased revenues as well as losses for the fourth quarter of 2003.


Revenues totaled $9.7 million, up from $7.6 million during the same period a year ago.


R&D expenses for the quarter were $3.8 million, slightly up from $3.3 million during the year-ago period. 


Third Wave recorded a net loss of $1.6 million, or $.04 per share, for the quarter, compared to $.5 million, or $.01 per share, during the same period in 2002.


As of Dec. 31, the company had cash, cash equivalents, and short-term investments of $57.8 million.


The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.